c-Met and hepatocyte growth factor: Potential as novel targets in cancer therapy

Cooper CS, Park M, Blair DG, et al.: Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature 1984, 311:29–33.

Rodrigues GA, Park M: Dimerization mediated through a leucine zipper activates the oncogenic potential of the met receptor tyrosine kinase. Mol Cell Biol 1993, 13:6711–6722.

Zhen Z, Giordano S, Longati P, et al.: Structural and functional domains critical for constitutive activation of the HGF-receptor (Met). Oncogene 1994, 9:1691–1697.

Gohda E, Tsubouchi H, Nakayama H, et al.: Human hepatocyte growth factor in plasma from patients with fulminant hepatic failure. Exp Cell Res 1986, 166:139–150.

Nakamura T, Nawa K, Ichihara A, et al.: Purification and subunit structure of hepatocyte growth factor from rat platelets. FEBS Lett 1987, 224:311–316.

Stoker M, Gherardi E, Perryman M, et al.: Scatter factor is a fibroblast-derived modulator of epithelial cell mobility. Nature 1987, 327:239–242.

Comoglio PM, Boccaccio C: The HGF receptor family: unconventional signal transducers for invasive cell growth. Genes Cells 1996, 1:347–354.

Maestrini E, Tamagnone L, Longati P, et al.: A family of transmembrane proteins with homology to the MET-hepatocyte growth factor receptor. Proc Natl Acad Sci U S A 1996, 93:674–678.

Stella MC, Comoglio PM: HGF: a multifunctional growth factor controlling cell scattering. Int J Biochem Cell Biol 1999, 31:1357–1362.

Gherardi E, Sandin S, Petoukhov MV, et al.: Structural basis of hepatocyte growth factor/scatter factor and MET signalling. Proc Natl Acad Sci U S A 2006, 103:4046–4051.

Stamos J, Lazarus RA, Yao X, et al.: Crystal structure of the HGF beta-chain in complex with the Sema domain of the Met receptor. Embo J 2004, 23:2325–2335.

Hammond DE, Urbe S, Vande Woude GF, et al.: Down-regulation of MET, the receptor for hepatocyte growth factor. Oncogene 2001, 20:2761–2770.

Teis D, Huber IA: The odd couple: signal transduction and endocytosis. Cell Mol Life Sci 2003, 60:2020–2033.

Kamada M, Komori A, Chiba S, et al.: A prospective study of congenital cytomegalovirus infection in Japan. Scand J Infect Dis 1983, 15:227–232.

Rodrigues GA, Park M: Autophosphorylation modulates the kinase activity and oncogenic potential of the Met receptor tyrosine kinase. Oncogene 1994, 9:2019–2027.

Abella JV, Peschard P, Naujokas MA, et al.: Met/Hepatocyte growth factor receptor ubiquitination suppresses transformation and is required for Hrs phosphorylation. Mol Cell Biol 2005, 25:9632–9645.

Petrelli A, Gilestro GF, Lanzardo S, et al.: The endophilin-CIN85-Cbl complex mediates ligand-dependent downregulation of c-Met. Nature 2002, 416:187–190.

Soubeyran P, Kowanetz K, Szymkiewicz I, et al.: Cbl-CIN85-endophilin complex mediates ligand-induced downregulation of EGF receptors. Nature 2002, 416:183–187.

Bache KG, Raiborg C, Mehlum A, et al.: STAM and Hrs are subunits of a multivalent ubiquitin-binding complex on early endosomes. J Biol Chem 2003, 278:12513–12521.

Ponzetto C, Bardelli A, Zhen Z, et al.: A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell 1994, 77:261–271.

Furge KA, Zhang YW, Vande Woude GF: Met receptor tyrosine kinase: enhanced signaling through adapter proteins. Oncogene 2000, 19:5582–5589.

Fournier TM, Kamikura D, Teng K, et al.: Branching tubulogenesis but not scatter of madin-darby canine kidney cells requires a functional Grb2 binding site in the Met receptor tyrosine kinase. J Biol Chem 1996, 271:22211–22217.

Bardelli A, Longati P, Gramaglia D, et al.: Gab1 coupling to the HGF/Met receptor multifunctional docking site requires binding of Grb2 and correlates with the transforming potential. Oncogene 1997, 15:3103–3111.

Weidner KM, Sachs M, Riethmacher D, et al.: Mutation of juxtamembrane tyrosine residue 1001 suppresses loss-of-function mutations of the met receptor in epithelial cells. Proc Natl Acad Sci U S A 1995, 92:2597–2601.

Gandino L, Longati P, Medico E, et al.: Phosphorylation of serine 985 negatively regulates the hepatocyte growth factor receptor kinase. J Biol Chem 1994, 269:1815–1820.

Bladt F, Riethmacher D, Isenmann S, et al.: Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud. Nature 1995, 376:768–771.

Schmidt C, Bladt F, Goedecke S, et al.: Scatter factor/hepatocyte growth factor is essential for liver development. Nature 1995, 373:699–702.

Uehara Y, Minowa O, Mori C, et al.: Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor. Nature 1995, 373:702–705.

Maina F, Klein R: Hepatocyte growth factor, a versatile signal for developing neurons. Nat Neurosci 1999, 2:213–217.

Patane S, Avnet S, Coltella N, et al.: MET overexpression turns human primary osteoblasts into osteosarcomas. Cancer Res 2006, 66:4750–4757.

Ichimura E, Maeshima A, Nakajima T, et al.: Expression of c-met/HGF receptor in human non-small cell lung carcinomas in vitro and in vivo and its prognostic significance. Jpn J Cancer Res 1996, 87:1063–1069.

Olivero M, Rizzo M, Madeddu R, et al.: Overexpression and activation of hepatocyte growth factor/scatter factor in human non-small-cell lung carcinomas. Br J Cancer 1996, 74:1862–1868.

Siegfried JM, Weissfeld LA, Singh-Kaw P, et al.: Association of immunoreactive hepatocyte growth factor with poor survival in resectable non-small cell lung cancer. Cancer Res 1997, 57:433–439.

Siegfried JM, Weissfeld LA, Luketich JD, et al.: The clinical significance of hepatocyte growth factor for non-small cell lung cancer. Ann Thorac Surg 1998, 66:1915–1918.

Tokunou M, Niki T, Eguchi K, et al.: c-MET expression in myofibroblasts: role in autocrine activation and prognostic significance in lung adenocarcinoma. Am J Pathol 2001, 158:1451–1463.

Stabile LP, Lyker JS, Land SR, et al.: Transgenic mice overexpressing hepatocyte growth factor in the airways show increased susceptibility to lung cancer. Carcinogenesis 2006, 27:1547–1555.

Rossi G, Cavazza A, Marchioni A, et al.: Role of chemotherapy and the receptor tyrosine kinases KIT, PDGFRalpha, PDGFRbeta, and Met in large-cell neuroendocrine carcinoma of the lung. J Clin Oncol 2005, 23:8774–8785.

Yi S, Tsao MS: Activation of hepatocyte growth factor-met autocrine loop enhances tumorigenicity in a human lung adenocarcinoma cell line. Neoplasia 2000, 2:226–234.

Jeffers M, Fiscella M, Webb CP, et al.: The mutationally activated Met receptor mediates motility and metastasis. Proc Natl Acad Sci U S A 1998, 95:14417–14422.

Maulik G, Kijima T, Ma PC, et al.: Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer. Clin Cancer Res 2002, 8:620–627.

Derman MP, Chen JY, Spokes KC, et al.: An 11-amino acid sequence from c-met initiates epithelial chemotaxis via phosphatidylinositol 3-kinase and phospholipase C. J Biol Chem 1996, 271:4251–4255.

Wang R, Ferrell LD, Faouzi S, et al.: Activation of the Met receptor by cell attachment induces and sustains hepatocellular carcinomas in transgenic mice. J Cell Biol 2001, 153:1023–1034.

Yu Y, Merlino G: Constitutive c-Met signaling through a nonautocrine mechanism promotes metastasis in a transgenic transplantation model. Cancer Res 2002, 62:2951–2956.

Tuck AB, Park M, Sterns EE, et al.: Coexpression of hepatocyte growth factor and receptor (Met) in human breast carcinoma. Am J Pathol 1996, 148:225–232.

Koochekpour S, Jeffers M, Rulong S, et al.: Met and hepatocyte growth factor/scatter factor expression in human gliomas. Cancer Res 1997, 57:5391–5398.

Li G, Schaider H, Satyamoorthy K, et al.: Downregulation of E-cadherin and Desmoglein 1 by autocrine hepatocyte growth factor during melanoma development. Oncogene 2001, 20:8125–8135.

Ferracini R, Di Renzo MF, Scotlandi K, et al.: The Met/HGF receptor is over-expressed in human osteosarcomas and is activated by either a paracrine or an autocrine circuit. Oncogene 1995, 10:739–749.

Giordano S, Corso S, Conrotto P, et al.: The semaphorin 4D receptor controls invasive growth by coupling with Met. Nat Cell Biol 2002, 4:720–724.

Schmidt L, Duh FM, Chen F, et al.: Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 1997, 16:68–73.

Hellman A, Zlotorynski E, Scherer SW, et al.: A role for common fragile site induction in amplification of human oncogenes. Cancer Cell 2002, 1:89–97.

Sakakura C, Mori T, Sakabe T, et al.: Gains, losses, and amplifications of genomic materials in primary gastric cancers analyzed by comparative genomic hybridization. Genes Chromosomes Cancer 1999, 24:299–305.

Smolen GA, Sordella R, Muir B, et al.: Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sci U S A 2006, 103:2316–2321.

Yokota S, Kiyoi H, Nakao M, et al.: Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines. Leukemia 1997, 11:1605–1609.

Lee JH, Han SU, Cho H, et al.: A novel germ line juxtamembrane Met mutation in human gastric cancer. Oncogene 2000, 19:4947–4953.

Peschard P, Fournier TM, Lamorte L, et al.: Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein. Mol Cell 2001, 8:995–1004.

Schmidt L, Junker K, Nakaigawa N, et al.: Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene 1999, 18:2343–2350.

Ma PC, Kijima T, Maulik G, et al.: c-MET mutaional analysis in small cell lung cancer: Novel juxtamembrance domain mutations regulating cytoskeletal functions. Cancer Res 2003, 63:6272–6281.

Zaffaroni D, Spinola M, Galvan A, et al.: Met proto-oncogene juxtamembrane rare variations in mouse and humans: differential effects of Arg and Cys alleles on mouse lung tumorigenesis. Oncogene 2005, 24:1084–1090.

Kong-Beltran M, Stamos J, Wickramasinghe D: The Sema domain of Met is necessary for receptor dimerization and activation. Cancer Cell 2004, 6:75–84.

Christensen JK, Schreck R, Burrows J, et al.: A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive anti-tumor activity in vivo. Cancer Res 2003, 63:7345–7355.

Cassinelli G, Lanzi C, Petrangolini G, et al.: Inhibition of c-Met and prevention of spontaneous metastatic spreading by the 2-indolinone RPI-1. Mol Cancer Ther 2006, 5:2388–2397.

Morotti A, Mila S, Accornero P, et al.: K252a inhibits the oncogenic properties of Met, the HGF receptor. Oncogene 2002, 21:4885–4893.

Sattler M, Pride YB, Ma P, et al.: A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase. Cancer Res 2003, 63:5462–5469.

Walz C, Sattler M: Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML). Crit Rev Oncol Hematol 2006, 57:145–164.

Bardelli A, Longati P, Williams TA, et al.: A peptide representing the carboxyl-terminal tail of the met receptor inhibits kinase activity and invasive growth. J Biol Chem 1999, 274:29274–29281.

Parr C, Hiscox S, Nakamura T, et al.: Nk4, a new HGF/SF variant, is an antagonist to the influence of HGF/SF on the motility and invasion of colon cancer cells. Int J Cancer 2000, 85:563–570.

Tomioka D, Maehara N, Kuba K, et al.: Inhibition of growth, invasion, and metastasis of human pancreatic carcinoma cells by NK4 in an orthotopic mouse model. Cancer Res 2001, 61:7518–7524.

Michieli P, Basilico C, Pennacchietti S, et al.: Mutant Met-mediated transformation is ligand-dependent and can be inhibited by HGF antagonists. Oncogene 1999, 18:5221–5231.

Martens T, Schmidt NO, Eckerich C, et al.: A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo. Clin Cancer Res 2006, 12:6144–6152.

Herynk MH, Stoeltzing O, Reinmuth N, et al.: Down-regulation of c-Met inhibits growth in the liver of human colorectal carcinoma cells. Cancer Res 2003, 63:2990–2996.

Shinomiya N, Gao CF, Xie Q, et al.: RNA interference reveals that ligand-independent met activity is required for tumor cell signaling and survival. Cancer Res 2004, 64:7962–7970.

Kamal A, Thao L, Sensintaffar J, et al.: A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 2003, 425:407–410.

Webb CP, Hose CD, Koochekpour S, et al.: The gel-danamycins are potent inhibitors of the hepatocyte growth factor/scatter factor-met-urokinase plasminogen activator-plasmin proteolytic network. Cancer Res 2000, 60:342–349.